Publications

Showing Publications By: Erika Lietzan

FDA Resilience after Loper Bright

__ SMU LAW REVIEW __ (forthcoming)

Petition Power

74 AMERICAN UNIVERSITY LAW REVIEW 107 (2024)

User Fee Programs

76 ADMINISTRATIVE LAW REVIEW 375 (Spring 2024)

Solutions Still Searching for a Problem: A Call for Relevant Data to Support “Evergreening” Allegations

33 FORDHAM INTELLECTUAL PROPERTY, MEDIA & ENTERTAINMENT LAW JOURNAL 788 (2023).

The Case of the Missing Device Patents, or: Why Device Patents Matter

33 FORDHAM INTELLECTUAL PROPERTY, MEDIA & ENTERTAINMENT LAW JOURNAL 409 (2022).

Ignoring Drug Trademarks

56 WAKE FOREST LAW REVIEW 945 (2021).

Early Access to Unapproved Medicines in the United States and France

19 YALE JOURNAL OF HEALTH POLICY, LAW, & ETHICS 1 (2020).

Distorted Drug Patents

95 WASHINGTON LAW REVIEW 1317 (2020).